GlassScriptPhysician profile
Harold W Helmke
NPI 1295736510
$31,601.09
in general payments reported to CMS, 2019-2025
50 companies · $3,238 in 2025
The $3,238 reported for 2025 was more than what 76% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,742 · 2020: $1,221 · 2021: $1,289 · 2022: $8,722 · 2023: $3,299 · 2024: $10K · 2025: $3,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $8,491 · Food and Beverage: $8,103 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $8,490.93 |
| Food and Beverage | $8,103.02 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $14,190.61 | 2021-2025 | Corevalve Evolut R, Onyx Frontier, Resolute Onyx |
| Edwards Lifesciences Corporation | $4,466.97 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbott Laboratories | $2,140.80 | 2019-2023 | 2nd Gen Centrimag Primary Console, Jot Dx |
| Shockwave Medical, INC | $1,390.66 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $1,171.37 | 2019-2025 | Comet, Avvigo Guidance System, Watchman Flx |
| Abiomed | $1,033.26 | 2019-2025 | Impella |
| Janssen Pharmaceuticals, INC | $959.14 | 2019-2024 | Xarelto |
| Ancora Heart, INC. | $751.16 | 2024 | Accucinch |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $565.26 | 2019-2025 | Lifevest |
| Philips North America LLC | $544.70 | 2025 | Azurion 7 M20 |
| Medtronic Vascular, INC. | $495.00 | 2019-2020 | |
| Amgen INC. | $490.75 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $407.65 | 2019-2025 | |
| Pfizer INC. | $404.90 | 2019-2025 | |
| Esperion Therapeutics, INC. | $319.82 | 2020-2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Helmke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.